The Thrombotic Microangiopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Thrombotic Microangiopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Thrombotic Microangiopathy. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Thrombotic Microangiopathy and features dormant and discontinued products.
GlobalData tracks ten drugs in development for Thrombotic Microangiopathy by nine companies/universities/institutes. The top development phase for Thrombotic Microangiopathy is phase i with three drugs in that stage. The Thrombotic Microangiopathy pipeline has ten drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Thrombotic Microangiopathy pipeline products market are: Omeros, Takeda Pharmaceutical and Alexion Pharmaceuticals.
The key targets in the Thrombotic Microangiopathy pipeline products market include Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5), Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104), and Leukotriene B4 (LTB4).
The key mechanisms of action in the Thrombotic Microangiopathy pipeline product include Mannan Binding Lectin Serine Protease 2 (Mannose Binding Protein Associated Serine Protease 2 or MBL Associated Serine Protease 2 or MASP2 or EC 3.4.21.104) Inhibitor with three drugs in Filing rejected/Withdrawn. The Thrombotic Microangiopathy pipeline products include six routes of administration with the top ROA being Subcutaneous and five key molecule types in the Thrombotic Microangiopathy pipeline products market including Monoclonal Antibody, and Small Molecule.
Thrombotic Microangiopathy overview
Thrombotic Microangiopathy is a life-threatening group of hematological diseases characterized by hemolytic anemia (destruction of red blood cells), thrombocytopenia, and microthrombi leading to ischemic tissue injury. In severe cases, TMA leads to kidney injury. Mutations in the ADAMTS13 gene and atypical hemolytic uremic syndrome cause TMA. It can also be caused by infectious diseases, blood-borne diseases, drug-induced etc. Complete blood count to analyze the levels of platelet, RBC, macrophages, and other tests for differential diagnosis. plasma exchange is the primary therapeutic option in which plasma (water and protein portion of blood) is removed from the body and replaced with fresh donor plasma followed by symptomatic care with corticosteroids, antibiotics etc.
For a complete picture of Thrombotic Microangiopathy’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
